Ausgabe 1/2019
Inhalt (22 Artikel)
Optimising intratumoral treatment of head and neck squamous cell carcinoma models with the diterpene ester Tigilanol tiglate
Catherine M. E. Barnett, Natasa Broit, Pei-Yi Yap, Jason K. Cullen, Peter G. Parsons, Benedict J. Panizza, Glen M. Boyle
Inhibiting IL-2 signaling and the regulatory T-cell pathway using computationally designed peptides
Tammy Price-Troska, Zhi-Zhang Yang, David Diller, Alexander Bayden, Mark Jarosinski, Joseph Audie, Stephen M. Ansell
Human acute myeloid leukemia cells express Neurokinin-1 receptor, which is involved in the antileukemic effect of Neurokinin-1 receptor antagonists
A. Molinos-Quintana, P. Trujillo-Hacha, J. I. Piruat, J. A. Bejarano-García, E. García-Guerrero, J. A. Pérez-Simón, Miguel Muñoz
Copper-tolfenamic acid: evaluation of stability and anti-cancer activity
Myrna Hurtado, Umesh T. Sankpal, Jaya Chhabra, Deondra T. Brown, Rajasekhar Maram, Rafid Patel, Raj K. Gurung, Jerry Simecka, Alvin A. Holder, Riyaz Basha
Discovering simple phenylboronic acid and benzoxaborole derivatives for experimental oncology – phase cycle-specific inducers of apoptosis in A2780 ovarian cancer cells
Mateusz Psurski, Agnieszka Łupicka-Słowik, Agnieszka Adamczyk-Woźniak, Joanna Wietrzyk, Andrzej Sporzyński
Immuno-therapeutic potential of Schistosoma mansoni and Trichinella spiralis antigens in a murine model of colon cancer
Maha M. Eissa, Cherine A. Ismail, Mervat Z. El-Azzouni, Amany A. Ghazy, Mona A. Hadi
Preclinical study of the antitumor effect of sphingosine-1-phosphate receptor 1 antibody (S1PR1-antibody) against human breast cancer cells
Shujun Xiao, Jian Yang
The poly (ADP-ribose) polymerase inhibitor rucaparib suppresses proliferation and serves as an effective radiosensitizer in cervical cancer
Mei Tang, Qiuli Liu, Leyuan Zhou, Ling Chen, Xueqing Yang, Jinjin Yu, Yuan Wang, Haifeng Qiu
Two phase I, pharmacokinetic, and pharmacodynamic studies of DFP-10917, a novel nucleoside analog with 14-day and 7-day continuous infusion schedules
Kamalesh Sankhala, Chris H. Takimoto, Alain C. Mita, Henry Xiong, Jordi Rodón, Amir Mehrvarz Sarshekeh, K. Burns, Kenzo Iizuka, Scott Kopetz
Phase Ib study of pevonedistat, a NEDD8-activating enzyme inhibitor, in combination with docetaxel, carboplatin and paclitaxel, or gemcitabine, in patients with advanced solid tumors
A Craig Lockhart, Todd M. Bauer, Charu Aggarwal, Carrie B. Lee, R Donald Harvey, Roger B. Cohen, Farhad Sedarati, Tsz Keung Nip, Hélène Faessel, Ajeeta B. Dash, Bruce J. Dezube, Douglas V. Faller, Afshin Dowlati
A phase Ib study of sonidegib (LDE225), an oral small molecule inhibitor of smoothened or Hedgehog pathway, in combination with docetaxel in triple negative advanced breast cancer patients: GEICAM/2012–12 (EDALINE) study
Manuel Ruiz-Borrego, Begoña Jimenez, Silvia Antolín, Jose A. García-Saenz, Jesús Corral, Yolanda Jerez, José Trigo, Ander Urruticoechea, Helena Colom, Nuria Gonzalo, Carmen Muñoz, Sara Benito, Rosalía Caballero, Susana Bezares, Eva Carrasco, Federico Rojo, Miguel Martín
Phase I study of resminostat, an HDAC inhibitor, combined with S-1 in patients with pre-treated biliary tract or pancreatic cancer
Masafumi Ikeda, Izumi Ohno, Hideki Ueno, Shuichi Mitsunaga, Yusuke Hashimoto, Takuji Okusaka, Shunsuke Kondo, Mitsuhito Sasaki, Yasunari Sakamoto, Hideaki Takahashi, Rina Hara, Shingo Kobayashi, Osamu Nakamura, Chigusa Morizane
A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma
Masafumi Ikeda, Manabu Morimoto, Masaomi Tajimi, Koichi Inoue, Karim A. Benhadji, Michael M. F. Lahn, Daisuke Sakai
Phase Ib trial combining capecitabine, erlotinib and bevacizumab in pancreatic adenocarcinoma - REBECA trial
Christian Dittrich, Robert Königsberg, Martina Mittlböck, Klaus Geissler, Azra Sahmanovic-Hrgovcic, Johannes Pleiner-Duxneuner, Martin Czejka, Philipp Buchner
Absorption, metabolism, and excretion of the antiemetic rolapitant, a selective neurokinin-1 receptor antagonist, in healthy male subjects
Zhi-Yi Zhang, Jing Wang, Vikram Kansra, Xiaodong Wang
First-in-human study of the anti-HB-EGF antibody U3-1565 in subjects with advanced solid tumors
Kathleen N. Moore, Johanna C. Bendell, Patricia M. LoRusso, Anthony J. Olszanski, Esther Zwick-Wallasch, Mendel Jansen, Alexander G. Vandell, Giorgio Senaldi
Phase 1 dose-escalation study of momelotinib, a Janus kinase 1/2 inhibitor, combined with gemcitabine and nab-paclitaxel in patients with previously untreated metastatic pancreatic ductal adenocarcinoma
Kimmie Ng, Andrew Hendifar, Alexander Starodub, Jorge Chaves, Yingsi Yang, Brian Koh, David Barbie, William C. Hahn, Charles S. Fuchs
Global trends in the distribution of cancer types among patients in oncology phase I trials, 1991–2015
Kota Itahashi, Toshio Shimizu, Takafumi Koyama, Shunsuke Kondo, Yutaka Fujiwara, Noboru Yamamoto
Advanced development of ErbB family-targeted therapies in osteosarcoma treatment
Wei Wang, Hua-fu Zhao, Teng-fei Yao, Hao Gong
Leptomeningeal recurrence after long-term alectinib therapy for non-small cell lung cancer harboring an EML4-ALK fusion protein
Takahisa Kawamura, Haruyasu Murakami, Haruki Kobayashi, Kazuhisa Nakashima, Shota Omori, Kazushige Wakuda, Akira Ono, Hirotsugu Kenmotsu, Tateaki Naito, Masahiro Endo, Toshiaki Takahashi
Antitumor evaluation of novel phenothiazine derivatives that inhibit migration and tubulin polymerization against gastric cancer MGC-803 cells
Nan Liu, Zhe Jin, Jing Zhang, Jianjun Jin